4 results match your criteria: "Perking University First Hospital[Affiliation]"
Complete response of recurrent malignant struma ovarii followed by I therapy.
J Obstet Gynaecol
January 2021
Department of Gynaecology and Obstetrics, Perking University First Hospital, Beijing, China.
Heteroplasmy and phenotype spectrum of the mitochondrial tRNA gene m.3243A>G mutation in seven Han Chinese families.
J Neurol Sci
January 2020
Department of Neurology, Tongren Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200336, China; Department of Neurology, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China. Electronic address:
The m.3243A > G mutation in the mitochondrial tRNA gene is associated with a variety of phenotypic heterogeneity. The clinical spectrum and phenotypic-genotypic correlations in the Chinese patients are poorly understood.
View Article and Find Full Text PDF[A retrospective analysis on the pernicious placenta previa from 2008 to 2014].
Zhonghua Fu Chan Ke Za Zhi
March 2016
Department of Obstetrics and Gynecology, Perking University First Hospital, Beijing 100034, China.
Objective: To investigate the incidence changes, clinical characteristics and pregnant outcomes of pernicious placenta previa.
Methods: A retrospective cohort analysis on 316 cases with placenta previa in the Peking University First Hospital from January 2008 to December 2014. The research group were 60 cases with the patients of placenta previa with the history of cesarean section, and the control group were placenta previa without the history of cesarean section.
[Diammonium glycyrrhizinate does not affect efficacy of adefovir dipivoxil therapy in patients with HBeAg-positive chronic hepatitis B].
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi
September 2007
Department of Infectious Diseases, Perking University First Hospital, Beijing, China.
Objective: To evaluate the effect of diammonium glycyrrhizinate on the antiviral therapy with adefovir dipivoxil (ADV) in patients with HBeAg-positive chronic hepatitis B.
Methods: Patients with HBeAg-positive chronic hepatitis B enrolled in this study were randomized to receive either ADV 10 mg/d fir 48 weeks or placebo for 24 weeks followed by ADV 10 mg/d for 24 weeks. Antiviral activities of diammonium glycyrrhizinate administered during the trial were studied with respect to virological and serologic response, and ALT normalization.